BACKGROUND: The purpose of the current study was to determine the incidence of late recurrences, which were defined as those occurring >or=5 years after initial therapy, among patients treated for salivary gland cancer. METHODS: Between 1960 and 2000, 145 patients underwent definitive therapy for localized carcinomas of the salivary glands and were clinically without evidence of disease at 5 years of follow-up. Cumulative probabilities for developing a subsequent late recurrence were estimated using the Kaplan-Meier method. RESULTS: The 10-year and 15-year cumulative probabilities of late recurrence in patients who were free of disease at 5 years were 13% and 18%, respectively. The crude rates of late recurrence by histologic subtype were adenoid cystic carcinoma (26%), mixed malignant tumor (25%), mucoepidermoid carcinoma (17%), adenocarcinoma (10%), and acinic cell carcinoma (8%). Sites of late recurrence included distant metastasis (17 patients), local recurrence (8 patients), and regional recurrence (2 patients). The median time to late recurrence was 7.1 years (range, 5.2-23.1 years) from the date of initial surgery. Salvage treatment varied according to location of disease recurrence and initial treatment characteristics. The 15-year estimate of overall survival was 39% for patients who experienced a late recurrence compared with 71% for those who remained free of disease (P= .001). CONCLUSIONS: A significant proportion of patients who are presumed to be cured of their disease at 5 years after initial treatment for salivary gland cancer will be found to develop late disease recurrence with additional follow-up.
BACKGROUND: The purpose of the current study was to determine the incidence of late recurrences, which were defined as those occurring >or=5 years after initial therapy, among patients treated for salivary gland cancer. METHODS: Between 1960 and 2000, 145 patients underwent definitive therapy for localized carcinomas of the salivary glands and were clinically without evidence of disease at 5 years of follow-up. Cumulative probabilities for developing a subsequent late recurrence were estimated using the Kaplan-Meier method. RESULTS: The 10-year and 15-year cumulative probabilities of late recurrence in patients who were free of disease at 5 years were 13% and 18%, respectively. The crude rates of late recurrence by histologic subtype were adenoid cystic carcinoma (26%), mixed malignant tumor (25%), mucoepidermoid carcinoma (17%), adenocarcinoma (10%), and acinic cell carcinoma (8%). Sites of late recurrence included distant metastasis (17 patients), local recurrence (8 patients), and regional recurrence (2 patients). The median time to late recurrence was 7.1 years (range, 5.2-23.1 years) from the date of initial surgery. Salvage treatment varied according to location of disease recurrence and initial treatment characteristics. The 15-year estimate of overall survival was 39% for patients who experienced a late recurrence compared with 71% for those who remained free of disease (P= .001). CONCLUSIONS: A significant proportion of patients who are presumed to be cured of their disease at 5 years after initial treatment for salivary gland cancer will be found to develop late disease recurrence with additional follow-up.
Authors: Alessandra Longhi; Costantino Errani; Marco Gambarotti; Christina Ferrari; Jennifer Kreshak; Georgios N Panagopoulos; Andreas F Mavrogenis; Davide Donati Journal: Eur J Orthop Surg Traumatol Date: 2015-07-15
Authors: Richard H Wiggins; John M Hoffman; Gabriel C Fine; Matthew F Covington; Ahmed Ebada Salem; Bhasker R Koppula; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-05-31 Impact factor: 6.575
Authors: Stephen B Keysar; Justin R Eagles; Bettina Miller; Brian C Jackson; Farshad N Chowdhury; Julie Reisinger; Tugs-Saikhan Chimed; Phuong N Le; John J Morton; Hilary L Somerset; Marileila Varella-Garcia; Aik-Choon Tan; John I Song; Daniel W Bowles; Mary E Reyland; Antonio Jimeno Journal: Clin Cancer Res Date: 2018-03-19 Impact factor: 12.531
Authors: Sergio V Cardoso; Kelen Christine N Souza; Paulo R Faria; Ana Lucia A Eisenberg; Fernando L Dias; Adriano M Loyola Journal: BMC Cancer Date: 2009-11-04 Impact factor: 4.430
Authors: Sana D Karam; Abdul Rashid; James W Snider; Margaux Wooster; Shilpa Bhatia; Ann K Jay; Kenneth Newkirk; Bruce Davidson; William K Harter Journal: Front Oncol Date: 2014-10-21 Impact factor: 6.244
Authors: Vivian P Wagner; Manoela D Martins; Esra Amoura; Virgilio G Zanella; Rafael Roesler; Caroline B de Farias; Colin D Bingle; Pablo A Vargas; Lynne Bingle Journal: Biomedicines Date: 2020-11-24